The US Food and Drug Administration (FDA) on Tuesday approved Kisunla (donanemab-azbt) injection, produced by Eli Lilly, for the treatment of Alzheimers disease. Kisunla is the third amyloid-targeting drug approved by the FDA since 2021, following two treatments Aduhelm and Leqembi. Kisunla slowed the cognitive and functional decline in patients with mild cognitive impairment by 35 percent over 18 months. The drug removes beta-amyloid that accumulates in the brains of patients with Alzheimer's disease. The estimated cost for a six-month course of the therapy is $12,522. A full year of treatment is protected to cost $32,000, according to Eli Lilly. Source: Qatar News Agency
Related Posts
Zakarneh Lamaa: An earthquake struck Jenin and the extent of the destruction is great
Jenin-Ma’an- Ali Zakarneh, a member of the Jenin and Camp Reconstruction Committee and a leader in the Fatah movement, said that the damage caused by the ongoing Israeli military operation in Jenin is like an “earthquake” and that the extent of the de…
Japan Issues Tsunami Advisory after 5.9-Magnitude Earthquake in the Pacific Ocean
The Japan Meteorological Agency issued a tsunami advisory for the Izu and Ogasawara islands shortly after a magnitude 5.9 earthquake occurred in the in the Pacific Ocean.
The epicenter of the earthquake was located in waters near Torishima in the Iz…
HRH the Crown Prince and Prime Minister receives Eid Al-Adha greetings from HH Shaikh Ali bin Khalifa Al Khalifa and HH Shaikh Salman bin Khalifa Al Khalifa
Manama, His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister, today received Eid Al-Adha greeting cables from the Advisor to HRH the Crown Prince and Prime Minister, His Highness Shaikh Ali bin Khalifa Al Khalifa,…